Sigyn Therapeutics (OTCQB:SIGY) appointed Richa Nand, Jim Dorst, and Christopher Wetzel to its board, effective Oct. 10, 2022. “As we transition toward the next phase of our clinical endeavors, it is an opportune...
Paul Brennan Paul Brennan is stepping down as president, CEO and a director of NervGen Pharma (OTCQX:NGENF; TSXV:NGEN), effective immediately. The board appointed current executive chairman, Bill Radvak, as interim CEO...
Verséa Holdings appointed Rob Sambursky, M.D., as president to support its corporate strategy and operations as well as lead the company’s expansion into the ophthalmic market. Verséa recently launched a new business...
Titan Pharmaceuticals (NASDAQ:TTNP) appointed Activist Investing’s David Lazar as interim chairman and CEO, with a mandate to lead Titan’s continuing review of strategic alternatives. He succeeds Marc Rubin, M.D...
Enzo Biochem (NYSE:ENZ) named Matthew Kupferberg as the company’s in-house general counsel. He was most recently general counsel, chief compliance officer and privacy officer of Digital Medical Technologies, a...
DURECT (NASDAQ:DRRX) appointed Timothy Papp as chief financial officer to direct and oversee all financial and capital markets activities, including accounting, financial reporting, financial planning and analysis...
Zymeworks (NYSE:ZYME) is strengthening its senior leadership team with the appointment of Paul Moore, Ph.D., as chief scientific officer, reporting directly to the CEO, effective July 18. Dr. Moore brings more than 25...
Anand Reddi, M.S. Hepion Pharmaceuticals (NASDAQ:HEPA) appointed Anand Reddi, M.S., and Kaouthar Lbiati, M.D., to its board of directors, effective immediately. “Mr. Reddi and Dr. Lbiati have a remarkable wealth...
Hepion Pharmaceuticals (NASDAQ:HEPA) appointed Launa Aspeslet, Ph.D., RAC, as chief operating officer to support the company’s rencofilstat clinical program. A versatile C-level executive with more than 25 years of...
Rodney Ouellette Soricimed Biopharma appointed one of Atlantic Canada’s leading cancer researchers, Rodney Ouellette, M.D. and Ph.D., to its scientific advisory board. “Rodney has dedicated his life’s work...
Schond Greenway Mind Medicine (NASDAQ:MNMD; NEO:MMED) appointed Schond Greenway as CFO. He comes to MindMed with more than 20 years of experience in investment banking, finance and corporate advisory, and investment...
Frank Michalargias Closely-held Soricimed Biopharma, an oncology drug developer, appointed healthcare industry veteran Frank Michalargias as CFO. In a finance and operations leadership career spanning more than 25...
Shishir Sinha Qualigen Therapeutics (NASDAQ:QLGN) appointed Shishir Sinha, the company’s newly promoted SVP and current COO, to lead its diagnostics division, FastPack. “With the return of the sales and...
Dr. Donald Hillebrand Sigyn Therapeutics (OTC:SIGY) appointed Dr. Donald Hillebrand, M.D., to its scientific advisory board. Dr. Hillebrand is the associate medical director of liver transplantation at Saint...
Francois Lilienthal Mind Medicine (NASDAQ, NEO:MNMD) appointed Francois Lilienthal, M.D., as chief commercial officer to support the advancement of the company’s clinical development programs. Dr. Lilienthal has...
Dipanjan Pan RNA Disease Diagnostics (RNADD) appointed its chief scientific advisor, Prof. Dipanjan Pan, Ph.D., and company president, John Erickson, Jr., to the board to further position RNADD to execute the next...
Ajay Verma Sigyn Therapeutics (OTC:SIGY) appointed Ajay Verma, M.D., Ph.D., a recognized thought leader in the field of neurology, to its scientific advisory board. Dr. Verma’s extensive clinical experience and insights...
After an absence of five years, Eric Cheng has rejoined Maxim Group as a senior managing director and head of healthcare investment banking. Mr. Cheng held similar titles at Maxim between 2011 and 2017. Mr. Cheng brings...
Anthony Petrone Mizuho Americas hired Anthony Petrone as a managing director, senior medical devices, diagnostics and therapeutics equity research analyst. Mr. Petrone has more than 16 years of experience in...
Sigyn Therapeutics (OTC:SIGY) appointed internationally recognized nephrologist, H. David Humes, M.D., to its scientific advisory board. Dr. Humes recently played an instrumental role in the oversight of preclinical...